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in a hypothetical ten-million member health plan over a 3-year horizon. Estimates 
of plan cancer rates and utilization of HEC and MEC therapies were derived from 
epidemiological and market data. Treatment costs were computed using standard 
prescribing dosages, U.S. drug cost listings and simple reimbursement and dis-
pensing assumptions. Uptake of NEPA was calculated at 5% a year for 3 years, and 
competing antiemetic therapies were reduced proportionately based on initial share 
assumptions. RESULTS: A total of 54,000 patients with cancer were identified in the 
model scenario. Of these, 9,882 (18.3%) would receive HEC and 3,949 (7.3%) would 
receive MEC requiring combination therapy, for a total of 13,830 eligible for NEPA. 
Cost of CINV prevention prior to the adoption of NEPA was estimated at $40.96 mil-
lion. Following adoption of NEPA, cumulative costs were reduced by nearly $652K by 
the end of year 3. Calculations using PMPM estimates showed cumulative savings 
of $0.002 in year 1, $0.004 in year 2, and $0.005 in year 3. CONCLUSIONS: Results of 
the model indicate that adoption of NEPA for the prevention of CINV may have a 
relatively neutral impact on a U.S. health plan budget. Additionally, these estimates 
do not include savings from a potential reduction in the overall rate of CINV.
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OBJECTIVES: To evaluate the cost of lung cancer treatment in Brazil from the 
perspective of private hospitals and identify the major cost drivers. METHODS: 
Orizon administrative claims database containing over 18 million lives was used 
to identify patients with lung cancer using the following ICD-10 codes: C34, C34.9, 
C34.0, C34.1, C34.3, C34.8, C34.2 between the period of November 2010 to October 
2013. Only patients receiving traditional chemotherapy for their lung cancer were 
included in the analysis. RESULTS: A total of 11,348 patients were identified with 
lung cancer over the analysis period. The study population was 54% men, 62 years 
old on average, and received treatment for a mean duration of 5,5 months. Of the 
11,348 patients, 3,076 were hospitalized and 8,272 received outpatient care. Forty-
nine percent of those hospitalized also received outpatient care. For patients who 
were hospitalized, each patient had, on average, 4.63 hospitalizations with an aver-
age length of stay of 9.55 days. The average cost per patient hospitalized was BRL 
34,904, with approximately 25.67% of the total hospital cost spent on drugs and the 
remainder spent on fees, supplies, exams and procedures (24.41%, 37.31%, 5.71% 
and 6.89% respectively). For outpatient care, the average cost per patient was BRL 
22,746 with 87.61% of the total outpatient care cost spent on drug expenses and 
the remainder spent on fees, supplies, exams, and procedures (1.73%, 4.02%, 3.76% 
and 2.88% respectively). CONCLUSIONS: The economic burden of lung cancer in 
Brazil could be reduced especially in outpatient care if oral treatments instead of 
infusion-based treatments were used (e.g., avoidance of infusion-related resources 
such as fees, procedures and supplies), which could represent a reduction of 8.63% 
or BRL 1,956 per lung cancer patient.
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OBJECTIVES: Clinical research has demonstrated that laparoscopic liver resec-
tion for hepatocellular carcinoma or secondary colorectal metastases provides 
oncologically equivalent patient outcomes when compared to open liver resection, 
while also providing a statistically significant reduction in postoperative complica-
tions. Approximately 16% of all liver resections in Canada are performed lapras-
copically with a compound annual growth rate of 16%. In the Canadian healthcare 
environment hospitals face constrained budgets and it is critical to demonstrate 
the impact of laparoscopic liver resection to increase procedure volume. This 
study was conducted to determine the budget impact of increasing the propor-
tion of laparoscopic vs. open liver resection in a Canadian hospital. METHODS: 
We examined the budget impact of increasing the percentage of laparoscopic liver 
cases from 16% to 40%, while decreasing the number of open cases proportion-
ately in a hospital that performs 50 resections annually. The model incorporates 
the costs associated with surgery, length of stay (taking into account facility and 
staff costs) and postoperative complications. The cost data used in the model 
was obtained from peer reviewed literature, the Ontario Case Costing Initiative 
and costing data from a large Canadian hospital. Data on patient outcomes was 
obtained from published meta-analyses. A multivariate sensitivity analysis using 
a Monte Carlo simulation was completed to ensure scientific rigour. RESULTS: 
Laparoscopic liver resections are associated with higher device costs, but similar 
overall procedure costs. The additional device cost is offset by a shorter length of 
stay and lower rate of post-operative complications. The model establishes that 
for a Canadian hospital performing 50 liver resections increasing the proportion 
of laparoscopic cases from 16% to 40% allows for a potential cost savings of CAD 
$50,730 annually. CONCLUSIONS: In a Canadian hospital, laparoscopic liver resec-
tion is a more cost-effective procedure for hepatocellular carcinoma or secondary 
colorectal metastases when compared to open resection.
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OBJECTIVES: Estimate the annual economic impact of the introduction of axitinib as 
a therapy for metastatic renal cell carcinoma (mRCC) in the budget of the Ministry 
0.50, p= 0.004), 12 (HR: 0.60, p= 0.009), and 18 (HR: 0.58, p= 0.002) months compared 
to patients receiving 1st-line chemo (patients with known site of metastases: 0.51 
[p= 0.031], 0.61 [p= 0.049], and 0.63 [p= 0.045], respectively) after adjusting for patient 
characteristics. CONCLUSIONS: Compared to chemotherapy, early endocrine ther-
apy may be associated with better survival in postmenopausal women with HR+/
HER2- mBC after adjusting for patient characteristics.
PCN32
adjuStiNg overaLL SurvivaL eStimateS For treatmeNt SwitCHiNg: a 
CaSe Study iN metaStatiC CaStratioN-reSiStaNt ProState CaNCer
Naidoo S.1, Ivanescu C.2, Skaltsa K.3, Phung D.4, Holmstrom S.5, Latimer N.6
1Astellas Pharma Europe, Ltd, Chertsey, UK, 2Quintiles, Hoofddorp, The Netherlands, 3Quintiles 
Consulting, Barcelona, Spain, 4Astellas Pharma Europe, Leiden, The Netherlands, 5Astellas 
Pharma Europe BV, Leiden, The Netherlands, 6University of Sheffield, Sheffield, UK
OBJECTIVES: In oncology trials, it is common practice to offer patients the possibility 
to switch from their randomized treatment to another active treatment upon dis-
ease progression. When patients switch to, and benefit from, active post-progression 
therapies which do not form part of the standard treatment pathway, a standard 
intention-to-treat (ITT) analysis may inaccurately estimate the ‘‘true’’ overall survival 
(OS) benefit associated with the investigational product [Latimer et al, 2014]. Using 
published data from the interim analysis of the PREVAIL study [Beer et al, 2014], 
we estimated the effects of enzalutamide compared to placebo on OS, adjusting for 
the potential confounding effects of switching to antineoplastic therapies that do 
not form part of the standard mCRPC treatment pathway in the UK. METHODS: 
Published treatment switching adjustment methods were applied including the 
Inverse Probability of Censoring Weights (IPCW) and a two-stage accelerated failure 
time model. The suitability of each method was evaluated by examining the study 
characteristics, the treatment switching mechanism, and by assessing the plausi-
bility of the underlying assumptions of the models in the context of the PREVAIL 
study. RESULTS: Overall, 180/845 (21%) patients in the placebo arm and 129/872 (15%) 
patients in the enzalutamide arm of PREVAIL switched to non-standard antineoplastic 
therapies. The unadjusted ITT analysis for OS resulted in a hazard ratio (HR) of 0.706 
(95% CI: 0.595 - 0.837) for enzalutamide compared to placebo, which was reduced 
to 0.662 (95% CI: 0.568 -0.809) using the two-stage method with no recensoring and 
0.625 (95% CI: 0.517 - 0.752) using the IPCW method. CONCLUSIONS: Adjusting for 
non-standard subsequent therapies given in PREVAIL resulted in a larger estimated 
treatment effect on OS associated with enzalutamide. This suggests that receipt of 
non-standard subsequent antineoplastic therapies caused the ITT analysis to under-
estimate the true treatment effect of enzalutamide on OS.
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OBJECTIVES: In the last 3 years, many new advanced melanoma treatments have 
come to market. Ipilimumab was the first compound to demonstrate a statistically 
significant improvement in overall survival in two Phase III RCTs and observational 
studies, with prolonged long-term survival up to 10 years. METHODS: Data from 
the advanced melanoma trials: CA184-024, MDX010-20 and BRIM-3 were used to 
develop an economic model in the UK and to predict the conditional survival of 
patients treated with ipilimumab, dacarbazine and vemurafenib who survived 2 
years. Dabrafenib, pembrolizumab and nivolumab were not valid UK comparators. The 
model uses patient level Kaplan–Meier data for the first 2 years for ipilimumab and 
dacarbazine, gompertz parametric curves fitted to patient level data from 2 to 5 years, 
and American Joint Committee on Cancer registry data from 5 years to 40 years. The 
curves were a good fit to the trial data and consistent with published longer-term data 
for ipilimumab (up to 10 years). Vemurafenib data were taken from the Roche submis-
sion to NICE, with covariate adjustment to account for differences in patient charac-
teristics between trials: M-stage, brain metastases, LDH, gender and ECOG. RESULTS: 
Once a previously untreated patient has survived 2 years, the modelled probability 
of being alive at 5 years is 70.9% for ipilimumab, 44.3% for dacarbazine and 50.2% for 
vemurafenib. At 10 years conditional survival is 45.4%, 28.4% and 31.6%, respectively; 
at 20 years 19.2%, 12.0% and 12.9%. Difference in mean survival was 1.2 years vs dac-
arbazine; 0.4 vs vemurafenib. CONCLUSIONS: A substantial proportion of patients 
treated with ipilimumab surviving to 2 years are likely to have a sustained survival 
benefit: 45.4% of such ipilimumab patients are alive at 10 years and 19.2% at 20 years. 
The level of sustained survival is lower with dacarbazine and vemurafenib.
CaNCer – Cost Studies
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OBJECTIVES: NCCN guidelines recommend a serotonin-3 receptor antagonist 
(5-HT3-RA), a substance P/neurokinin 1 (NK1) receptor antagonist, and dexametha-
sone for patients undergoing highly emetogenic chemotherapy (HEC) for the preven-
tion of chemotherapy-induced nausea and vomiting (CINV). This same combination 
is also recommended in patients using moderately emetogenic chemotherapy (MEC) 
at higher risk for CINV. This study estimated the budget impact of adopting netupi-
tant/palonosetron (NEPA), an oral fixed-dose combination of a 5-HT3-RA and an NK1 
for antiemetic prophylaxis, from a U.S. health plan perspective. METHODS: A deci-
sion analytic model compared treatment costs before and after adoption of NEPA 
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ASP per therapy. RESULTS: Annual net reimbursement revenues per patient based 
on 340B acquisition costs were projected to be $53,270 for dabrafenib+trametinib 
combination, $27,043 for vemurafenib, $22,634 for dabrafenib, and $19,029 for 
trametinib. CONCLUSIONS: The addition of user-modifiable projected reimburse-
ment revenue calculation is a valuable tool that expands the contribution of eco-
nomic modeling to hospital formulary decision-making.
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OBJECTIVES: Strategies for screening incident colorectal cancers(CRC) for possible 
Lynch syndrome(LS) are evolving rapidly. Our objective is to compare the diagnos-
tic results and costs from two strategies for LS screening: Targeted Screening(TS) 
and Universal Screening(US) of tumors for mismatch repair(MMR) abnormali-
ties. METHODS: For 18-months in 2010-2011, we employed TS - individuals under 
60 years old and those meeting Bethesda criteria for LS. In 2012, we began US of all 
CRC. Immuno-histochemical(IHC) staining for the four MMR proteins was done in all 
cases. Microsatellite instability, BRAF mutation, MLH1 promoter methylation testing, 
and/or genetic testing of germ line DNA were done in selected cases. We modeled 
the diagnostic costs of several strategies for detecting LS, and the downstream costs 
of prevention CRC through colonoscopy screening, using a system dynamics model, 
built in the “Anylogic” program. RESULTS: In 2010-2011, 51 of 175 (29%) incident 
CRCs were screened by IHC using TS strategy; 15(29%) showed abnormal loss of 
> 1 MMR protein. Germ line MMR gene mutations were found in 4 cases and were 
suspected but not demonstrated in 11 additional cases. In 2012-2013, 194 CRCs were 
screened by IHC using US; 13(6.7%) of CRCs had abnormal staining suspicious for 
LS. MMR mutations were found in only 2/9 cases abnormal for IHC. Cost to identify 
the LS probands was ~$8,339/LS case diagnosed for targeted screening (four muta-
tion carriers/18 months) and ~$32,708/LS case diagnosed for universal screening 
(two mutation carriers/24 months). CONCLUSIONS: Real-world results were more 
complicated than anticipated. Results from US with IHC were often atypical, not 
diagnostic of LS. Economic analysis using our costs suggests that TS is less costly 
than US, but it will miss some cases of mildly penetrant LS. US identifies changes 
that are currently of unknown significance but that have potential to contribute to 
future research into the mechanisms of CRC tumorigenesis.
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OBJECTIVES: Little is known about cancer (CA) in hospitalization, cost and out-
comes in transitional countries. We studied this in a multicentric hospital study 
in Argentina. METHODS: Adult CA, hospital direct costs, re-admissions (ReH < 30 
days) and deaths in 1 yr output of 3 academic hospitals. Cost and results, harmo-
nized according HCUPS (USA) terminology groupers, of primary (1Dx), and second-
ary diagnosis (2Dx) for each CCS code (Clinical Classification Software-CCS single 
level-SL, 2009). Total costs (CT$), mean costs (SD) and median per discharge cost 
($, 25P-75P-percentiles), in Itl.$ PPP, (UN Data: 1Arg$ = 1.608 PPP, 2008). CA defined 
as (#CCS [descriptive term]), including from CCS #11 [head and neck CA] to #44 
[Neoplasms of unspecified nature or uncertain behavior] and CCS 45 [Maintenance 
chemotherapy; radiotherapy--QT;RT]. Readmisions (ReH) < 30 days and hospital 
deaths were obtained. RESULTS: Among 45 466 ≥ 19 yrs.old, CA was found in 6 
282, 13,81%(95%CI 13,50-14,14) Dx1; CCS 11-45 (F= 49,33%) (individual CA data not 
shown) while QT;RT (# 45) = 2 520 disch., 5,54% (4,75-5,15). Among CCS 45 [QT;RT] en 
1Dx, CCS #11-44 in any 2Dx up to 5 2Dx code adds 3,046 disch; adding CA codes 1Dx 
+2Dx = 9.298 discharges (20,45%, 20,08-20,82). Among CCS en 1Dx, CT $ = I $ PPP 64 
088 727; mean: I$ 17,035; SD: I$ 4,276; median: I$ 8,897 (25P 4,042; 75 P 19,601). ReH 
< 30 d = 485 (1,06 %, 0.97-1,16); while QT-RT (#45) ReH< 30 = 1,754 (3,86%, 3,68-4,04). 
Case fatality rate for CCS 11-44 was 3,27%,(2,86-3,74), and for CCS 45 was 0,17%,( 
0,06-0,45). CONCLUSIONS: CA burden among hospital discharges, and its costs, case 
fatality, and readmisions were obtained for the first time in Argentina. QT-RT as a 
first Dx is close to half of discharges, and showing CA en 2Dx behaves differently in 
ReH and mortality. An iceberg phenomenon of CA in 2Dx emerges.
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OBJECTIVES: Real-world data may inform decisions regarding treatment for renal 
cell carcinoma (RCC). We compared treatment persistence and healthcare costs for 
sunitinib and pazopanib, considering dosing cycle differences’ effect on days sup-
ply. METHODS: This retrospective cohort study used the Truven Marketscan® data-
base. Inclusion criteria were RCC diagnoses, age ≥ 20 years, ≥ 1 (index) prescription 
for sunitinib or pazopanib 10/1/2009 – 9/30/2013, and continuous plan enrollment ≥ 6 
months before to 12 months after index. We compared demographic and clinical char-
acteristics and treatment patterns, using Chi-square, Student t-test, and Wilcoxon 
signed-rank test (α = 0.05). Costs were compared using generalized linear modeling 
to adjust for demographic, clinical, and medication variables. Sensitivity analysis 
assessed effects of imputing days supply for sunitinib’s 42-day dosing for prescrip-
tions with 28 or 30 days supply. RESULTS: Among 466 patients (77% receiving suni-
tinib), the cohorts were not significantly (NS) different in demographics or Charlson 
Comorbidity Index. More sunitinib patients (46 vs. 6 pazopanib patients; p= 0.038) had 
of public healthcare in Ecuador to predict the financial consequences of introducing 
axitinib as a second line treatment in Ecuador. METHODS: Using a budget Impact 
analysis model, we estimated the incremental impact in the Ministry of public 
healthcare budget in Ecuador with the introduction of axitinib as treatment for 
mRCC in whom have failed the first line treatment. The comparative used drugs 
were sorafenib, everolimus, sunitinib, pazopanib and bevacizumab + IFNa. The epi-
demiological data was taken from GLOBOCAN 2012. The costs information 2014 was 
obtained from public sources and the model was built in Microsoft Excel 2007. The 
economic analysis is based in the incidence of RCC: metastatic, non-metastatic 
and the percentage of the patients with progression. The model considers two sce-
narios: 1) The current market of treatment without Axitinib, 2) The current market 
adding Axitinib. RESULTS: Based on the incidence of RCC and the Ecuador popula-
tion, we calculated 269 incident cases of RCC, 211 with metastatic disease and 58 
who will progress to metastatic disease, 97 patients received a first line treatment 
of whom 40.91% (40 patients) needed a 2ndline treatment. Along a 3 year follow-
up in the scenario were axitinib was added, the estimated cost was $5,810,416.84 
USD, with an incremental change of $26,098.99 USD and an incremental cost for 
the population with access to the national healthcare system of $0.00010 USD p/
month. CONCLUSIONS: The addition of axitinib as a second line treatment for 
mRCC had a minimal impact on the budget designated to the Ministry of public 
healthcare in Ecuador, and since it has an A1 recommendation level, it will represent 
an improvement in the mRCC treatment options.
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OBJECTIVES: Prostate cancer is the second leading cause of cancer death in 
American men and has a high economic burden. Enzalutamide received FDA 
approval for an expanded indication based on significant improvement in overall 
survival and radiographic progression-free survival in chemotherapy-naïve meta-
static castration-resistant prostate cancer (mCRPC) patients. Our objective was to 
estimate the 1-year budget impact (BI) of adopting enzalutamide’s expanded indica-
tion. METHODS: Epidemiologic data, including SEER incidence rates, were used to 
estimate total number of chemotherapy-naïve mCRPC patients in a hypothetical 
1-million member U.S. health plan. Treatment options included abiraterone acetate, 
sipuleucel-T, radium-223 dichloride, and docetaxel. Dosing, administration, mean 
duration of therapy and adverse event (AE) rates were based on package inserts 
and pivotal studies. Drug costs (including pre- and concomitant medications) were 
obtained from RedBook and CMS ASP pricing files, administration and monitoring 
from CMS Physician Fee Schedule, and AEs from AHRQ H-CUP and published litera-
ture. Drug utilization was estimated for each comparator before and after adoption 
of enzalutamide. Incremental aggregate budget, per patient per year (PPPY), per 
patient per month (PPPM), and per member per month (PMPM) impact were cal-
culated. One-way sensitivity analyses were performed. RESULTS: In an estimated 
population of 115 mCRPC patients, adopting the new enzalutamide indication 
had modest annual plan impact ($510,641 incremental aggregate BI, $4,426 PPPY, 
$368.83 PPPM and $0.04 PMPM). Enzalutamide acquisition cost was partially offset 
by moderate AEs and no additional monitoring costs. Results were most sensitive 
to enzalutamide drug cost, size of chemotherapy-naïve mCRPC patient population 
and enzalutamide adoption rate. CONCLUSIONS: Results indicate a modest 1-year 
BI to adopt enzalutamide for chemotherapy-naïve mCRPC patients, partly due to the 
cost offset of moderate incidence of AEs and lack of additional required monitoring. 
Further analysis to understand cost per clinical outcome may complement the BI 
model to understand relative costs and benefits.
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OBJECTIVES: Economic modeling is an accepted tool for making formulary decisions 
by payers in the US. Hospital and institutional healthcare providers have expressed 
increased interest in using economic modeling in their decision making processes, 
particularly regarding potential reimbursement based on hospital-specific pricing. 
This study presents hospital perspective results from a revenue impact (RI) calcula-
tor component of an economic model. METHODS: An economic model was devel-
oped that investigated the RI (pharmaceutical acquisition costs minus projected 
reimbursement) of introducing National Comprehensive Cancer Network Category 1 
recommended therapies for BRAF V600 mutated metastatic melanoma to a hospital 
formulary. Therapies investigated in the analysis included: dabrafenib+trametinib 
combination therapy, vemurafenib monotherapy, dabrafenib monotherapy, and 
trametinib monotherapy. The model calculated the annual pharmaceutical acqui-
sition cost of each therapy based on recommended dosing, progression-free survival 
as a marker for duration of treatment, and drug pricing. Pricing data was retrieved 
from the Truven Health Analytics RED BOOK™ database. Acquisition costs in the 
model could be set to 340B, wholesale acquisition cost (WAC), or average wholesale 
price (AWP) values. The model used a default 30% discount compared to WAC to 
approximate 340B pricing. The projected reimbursement in the model uses WAC 
plus a modifiable 4.3% (based on the Medicare permitted reimbursement premium) 
for both Medicare and commercial payers. The perspective payer mix and respec-
tive reimbursement percentages can be modified by the model user. WAC was used 
in place of average sales price (ASP) due to the unavailability of hospital-specific 
